## Management of Refractory Menière Disease **Key Point:** When medical therapy (diuretics + sodium restriction) fails after an adequate trial (≥ 12–18 months), the next step is **intratympanic gentamicin injection** — a minimally invasive, ablative procedure that controls vertigo in 60–80% of refractory cases while preserving hearing better than surgical labyrinthectomy. ### Classification of Menière Disease Severity | Severity | Vertigo Frequency | Hearing Loss | Management | |----------|------------------|--------------|-------------| | Mild | < 1 attack/month | Stable or minimal | Sodium restriction, diuretics, vestibular rehab | | Moderate | 1–4 attacks/month | Progressive | Optimize medical therapy, consider intratympanic agents | | Severe/Refractory | > 4 attacks/month OR failed medical therapy | Significant progressive loss | Intratympanic gentamicin, labyrinthectomy, or vestibular neurectomy | ### Escalation Pathway for Refractory Disease ``` Menière Disease → First-line: Sodium restriction + Diuretics + Vestibular rehab → Response at 12–18 months? YES → Continue medical therapy NO → Refractory Menière → Hearing preservation priority? YES → Intratympanic gentamicin (or dexamethasone) NO → Labyrinthectomy or vestibular neurectomy ``` ### Why Intratympanic Gentamicin Is the Next Step 1. **Mechanism:** Gentamicin is a vestibulotoxic aminoglycoside that selectively ablates vestibular hair cells, reducing endolymphatic hydrops-driven vertigo 2. **Efficacy:** Controls vertigo in 60–80% of refractory cases (AAO-HNS guidelines) 3. **Hearing preservation:** Preferentially targets vestibular epithelium over cochlear epithelium; far safer than labyrinthectomy (which causes complete hearing loss) 4. **Minimally invasive:** Transtympanic injection; no general anesthesia required 5. **Guideline-endorsed:** AAO-HNS Menière Disease Clinical Practice Guidelines (2020) recommend intratympanic gentamicin as the preferred ablative intervention after medical failure **High-Yield:** Intratympanic gentamicin is the **gold standard for refractory Menière disease when hearing preservation is still a priority**. ### Why Other Options Are Incorrect **Option A (Increase diuretics + add acetazolamide):** This patient has already completed 18 months of adequate medical therapy with documented failure. Further dose escalation is unlikely to provide benefit and inappropriately delays definitive treatment. AAO-HNS guidelines do not recommend escalating diuretic therapy as a step beyond initial failure. **Option C (Surgical referral — endolymphatic sac decompression or vestibular neurectomy):** These are appropriate for truly intractable disease, but they are more invasive than intratympanic gentamicin and are reserved for cases that fail intratympanic therapy or when hearing is already severely compromised. Jumping to surgery before a minimally invasive ablative option is not the recommended next step. **Option D (Betahistine + MRI):** Two issues here: - *Betahistine:* While widely prescribed in India and parts of Europe, betahistine lacks robust evidence in major Western guidelines (AAO-HNS, Cochrane reviews). More importantly, this patient has already failed 18 months of medical therapy — adding betahistine at this stage is not the most appropriate next step per standard escalation protocols. - *MRI:* MRI to exclude vestibular schwannoma or other mimics is a reasonable consideration in any patient with progressive unilateral SNHL, and the SME note correctly flags that the claim "MRI is not indicated" is slightly strong. However, in this clinical scenario the diagnosis of Menière disease is already established over 3 years, and ordering MRI at this point would delay definitive treatment without changing immediate management. MRI can be arranged in parallel but is not the *most appropriate next step* for managing refractory vertigo. **Clinical Pearl:** Intratympanic gentamicin can cause delayed sensorineural hearing loss in 5–10% of patients; baseline audiometry and follow-up testing are essential. Intratympanic dexamethasone is an alternative if hearing preservation is the overriding concern, though gentamicin is more effective for vertigo control. **Note on Regional Practice:** In India, betahistine is commonly prescribed as part of Menière management. However, for NEET PG/INI-CET purposes, the standard escalation after documented medical failure is intratympanic gentamicin, not addition of betahistine. **Mnemonic:** **GIFT** = Gentamicin Intratympanic For refractory Tinnitus/vertigo [cite: AAO-HNS Menière Disease Clinical Practice Guidelines 2020; Harrison's Principles of Internal Medicine 21e Ch 468; Scott-Brown's Otorhinolaryngology 8e]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.